Immunoglobulin E (IgE) plays a crucial role in the occurrence and development of allergic diseases. Since the discovery of IgE in 1967, the pathogenesis of allergic inflammatory diseases has been progressively revealed thereby providing a theoretical foundation for the development of therapeutic anti-IgE antibodies, which have emerged as a new method for the treatment of allergic diseases. In this paper, we aim to summarize and elaborate on the mechanism of biological effects and clinical application of anti-IgE antibodies by examining related global literature, particularly regarding Omalizumab in the past 5 years. We seek to establish theoretical foundations for the formation of new strategies for anti-allergic treatment.
S. Karger AG, Basel.